Who is sponsoring NCT04968028?

NCT04968028 is sponsored by Shanghai Changzheng Hospital.

What drugs are being tested in NCT04968028?

Interventions in NCT04968028: ACAF, Laminoplasty.

What condition does NCT04968028 study?

NCT04968028 studies Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy.

Is NCT04968028 still recruiting?

NCT04968028 is currently recruiting now. Last updated 17 April 2024.

Last reviewed 2024-04-17 · How we verify

NCT04968028

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament

Recruiting now NA Last updated 17 April 2024

What this trial tests

NA trial testing ACAF in Ossification of Posterior Longitudinal Ligament in 164 participants. Currently enrolling.

Timeline

17 August 2021

Primary endpoint
31 July 2025

31 December 2026

Quick facts

Lead sponsor	Shanghai Changzheng Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	164
Start date	17 August 2021
Primary completion	31 July 2025
Estimated completion	31 December 2026
Sites	12 locations across China

Drugs / interventions tested

ACAF
Laminoplasty

Conditions studied

Ossification of Posterior Longitudinal Ligament — all drugs for Ossification of Posterior Longitudinal Ligament →
Cervical Spondylosis With Myelopathy — all drugs for Cervical Spondylosis With Myelopathy →

Sponsor

Shanghai Changzheng Hospital

Who can join

Adults 18 to 70, any sex, with Ossification of Posterior Longitudinal Ligament or Cervical Spondylosis With Myelopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the efficacy, safety and imaging outcomes between Anterior Controllable Antedisplacement and Fusion (ACAF) and Laminoplasty in the treatment of severe ossification of cervical posterior longitudinal ligament.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Changzheng Hospital trials

Trials by the same sponsor.

NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04968028 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
Last refreshed: 17 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04968028.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing